Developments in cardiometabolic care for the primary care physician
The primary care team, including nurse practitioners and physician assistants, is often the first to evaluate and assess chronic conditions and interconnected comorbidities, such as steatotic liver disease, renal disease and Type 2 diabetes (T2D), using diagnostic assays. Use of evidence-based strategies for early detection and effective management of cardiovascular-kidney-metabolic (CKM) conditions is crucial for optimal patient outcomes.
In this webinar, Dr. Kenneth Cusi, Professor of Medicine at the Division of Endocrinology, Diabetes & Metabolism in the Department of Medicine at the University of Florida, Gainesville, will help you explore the latest therapeutic and diagnostic developments in renal and liver manifestations of metabolic disease for busy primary care practitioners. This includes popular topics such as the use of GLP-1 and dual agonists for weight and metabolic disease management.
Topics covered:
- Progression of cardiorenal and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) in people with obesity or Type 2 diabetes by better understanding their shared metabolic defects
- Lessons from the latest studies on GLP-1 receptor agonist therapy to cardiorenal and liver disease
- The 2024 American Diabetes Association diagnostic and treatment recommendations for MASLD in the context of obesity and Type 2 diabetes
Labcorp can be your lab partner in the assessment of cardiometabolic conditions.